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ABSTRACT 
The RING E3 ligase catalysed formation of lysine 63 linked ubiquitin 
chains by the Ube2V2–Ubc13 E2 complex is required for many important 
biological processes. Here we report the structure of the RING domain 
dimer of rat RNF4 in complex with a human Ubc13~Ub conjugate and 
Ube2V2. The structure has captured Ube2V2 bound to the acceptor 
(priming) ubiquitin with Lys63 in a position that could lead to attack on 
the linkage between the donor (second) ubiquitin and Ubc13 that is held 
in the active “folded back” conformation by the RING domain of RNF4. 
The interfaces identified in the structure were verified by in vitro 
ubiquitination assays of site directed mutants. This represents the first 
view of the synthesis of Lys63 linked ubiquitin chains in which both 
substrate ubiquitin and ubiquitin-loaded E2 are juxtaposed to allow E3 
ligase mediated catalysis.  
 
INTRODUCTION 
Ubiquitin is a flexible and reversible signal that serves to alter the fate of the 
protein to which it is conjugated. Modification by ubiquitin is mediated by an 
enzymatic cascade in which ubiquitin is initially linked via a thioester bond to 
one of two ubiquitin activating enzymes. The ubiquitin then undergoes a 
transthiolation reaction onto one of about 40 different ubiquitin conjugating 
enzymes (E2s) which then interact with one of the 600 substrate specific 
ubiquitin E3 ligases1,2. RING E3 ligases prime the ubiquitin loaded E2 for 
catalysis by a mechanism of conformational selection in which RING residues 
contact both the E2 and donor ubiquitin, immobilising the ubiquitin and locking 
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its C-terminus into a groove on the E23-5. It is thought that immobilising the 
donor ubiquitin onto the E2 will orientate the thioester between ubiquitin and 
the E2 in an optimal orientation to undergo nucleophilic attack by the -amino 
group of a lysine in the substrate6.  If the attacking lysine residue is from 
another molecule of ubiquitin then this will result in the formation of an 
isopeptide bond between two ubiquitin molecules and if repeated multiple 
times will result in the generation of a ubiquitin chain. Ubiquitin contains 7 
lysine residues and all, along with the N-terminal amino group of ubiquitin, can 
be utilised to form the 8 different di-ubiquitin species.  
 
We had previously shown that the SUMO Targeted Ubiquitin E3 Ligase 
(STUbL) RNF4 was responsible for the UbcH5A catalysed formation of K48 
chains that targeted SUMO modified PML protein for proteasomal degradation 
in response to arsenic treatment7. It is also involved in the mammalian DNA 
damage response, facilitating DNA repair8-11. SUMO chains bind SUMO 
interaction motifs of RNF4 inducing dimerization of the RING domain, which is 
required for its function as an E3 ligase12. Thus, RNF4 is recruited to DNA 
damage sites by recognition of SUMO-modified DNA damage associated 
proteins such as MDC1 where it is responsible for the formation of K63 linked 
ubiquitin chains that are involved in signaling DNA damage repair11. K63 
linked ubiquitin chains are synthesised by the E2 enzyme Ubc13, but only 
when it is complexed with UEV (Ube2V1 and Ube2V2 in humans and MMS2 
in yeast), a pseudo E213 that serves to orientate the acceptor ubiquitin such 
that the K63 can attack the thioester linking the donor ubiquitin to Ubc1314. In 
the case of K63 chain formation the substrate is an acceptor ubiquitin that is 
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positioned by UEV, but as yet there are not structures available of an acceptor 
ubiquitin that is poised to attack the thioester of a donor ubiquitin held in place 
by an activating ubiquitin E3 ligase. To address this question we have 
determined a structure of the RING domain dimer of RNF4 in complex with a 
Ubc13~Ub conjugate and Ube2V2. The structure has captured K63 in the 
acceptor ubiquitin in a position that could lead to attack on the active site of 
Ubc13 that is linked to the donor ubiquitin. Biochemical analysis suggests that 
in addition to positioning the acceptor ubiquitin Ube2V2 is also required for 
RNF4 mediated activation of the Ubc13~Ub thioester.  
 
RESULTS 
RNF4 dependent synthesis of K63 chains by Ube2V2 and Ubc13 
We had previously shown that in response to DNA damage the STUbL RNF4 
(Fig. 1a) was responsible for the formation of K63 linked ubiquitin chains11. 
We therefore tested the ability of RNF4, Ubc13 and Ube2V2 to catalyse K63 
chain synthesis on a ubiquitin-primed tetraSUMO substrate (Fig. 1a). Ubc13 
combined with Ube2V2 efficiently generated K63 chains linked to ubiquitin-
primed tetraSUMO substrate in the presence of RNF415 but crucially Ubc13 
alone is inactive even in the presence of RNF4 (Fig. 1b).  In the absence of 
substrate a low level of unanchored K63 chains were generated (Fig. 1b) and, 
as visualised by Western blotting (Supplementary Fig. 1a) K63 chain 
synthesis was stimulated by the presence of tetraSUMO lacking the N-
terminal ubiquitin although tetraSUMO itself was not a substrate for ubiquitin 
modification. This is consistent with SUMO chain-induced dimerization as a 
mechanism for RNF4 activation12 and for the requirement of a ubiquitin-
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modified (also known as priming) substrate. 
 
Structure of Ubc13~ubiquitin–Ube2V2–RNF4 RING complex 
To establish the molecular basis of the RNF4 catalysed synthesis of K63 
chains by Ube2V2-Ubc13 we determined structures of ubiquitin-loaded Ubc13 
(Ubc13~Ub) in complex with the RING domain of RNF4 in the presence (Fig. 
2a) and in the absence (Fig. 2b) of Ube2V2 (Table 1). We used a stable 
isopeptide linked E2~Ub to mimic the unstable thioester4 (Supplementary Fig. 
1b–e). The Ubc13~Ub–RNF4 RING structure closely resembles that 
described previously for UbcH5A~Ub–RNF4 RING4 (Supplementary Fig. 2a). 
In these complexes the RNF4 RING dimer sits at the centre with a two-fold 
rotational axis of symmetry relating the RNF4 RING domains. The 
Ubc13~Ub–Ube2V2–RNF4 structure (Fig. 2a) lacks the two-fold symmetry of 
the Ubc13~Ub–RNF4 RING and UbcH5A~Ub–RNF4 RING complexes, 
therefore we discuss each “half” split at the RNF4 RING domains separately. 
In one half the Ubc13~Ub conjugate is bound to the RING domain, as seen in 
the Ubc13~Ub–RNF4 RING structure (Supplementary Fig. 2b) and a Ube2V2 
is bound to Ubc13 engaging the surface opposite to that docked to the RING. 
In the other half of the structure, the RING, Ubc13 and Ube2V2 adopt the 
same configuration as described above however ubiquitin is found in an 
unexpected location. In the asymmetric unit one of the ubiquitin molecules 
tethered by the isopeptide bond to the E2, appears to project away from the 
complex (Fig. 2a).  However analysis of packing of the molecules in the 
crystal reveals the reason for the displaced ubiquitin; it makes extensive 
contacts with a symmetry related Ube2V2 molecule and thus mimics the 
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priming (substrate-bound) ubiquitin (Fig. 2c and Supplementary Fig. 3a).  
 
By selecting a different symmetry related ubiquitin within the Ubc13~Ub–
Ube2V2–RNF4 RING crystal structure, a model that has captured Ube2V2 
bound to the acceptor ubiquitin can be created. The donor ubiquitin is held in 
the activated “folded back” conformation by the RING domain of RNF4 seen 
previously4, while the acceptor ubiquitin is oriented by Ube2V2 such that its 
K63 is in a position that could lead to attack the thioester linkage between the 
donor ubiquitin and Ubc13 (Supplementary Fig. 3b–e). In the present 
structure the amino group of K63 is 12.5 Å from the active site of Ubc13, 
but relatively minor adjustments of the components of the complex could bring 
the lysine residue into a position where it would be close enough to carry out 
nucleophilic attack on the thioester between ubiquitin and Ubc13. This 
arrangement in the crystal is thus a structural model for all components 
required to transfer a ubiquitin onto Lys63 of another ubiquitin molecule; the 
first step in the synthesis of K63 chains (Fig. 2d).  
 
Validation of the Ubc13~Ub–Ube2V2–RNF4 RING structure  
The validity of this model is supported by an analysis of the individual protein-
protein interfaces. The interfaces between E3 ligase and E2~Ub, between 
ubiquitin and the pseudo E2 and between Ubc13 and the pseudo E2 have 
been observed previously3-5,14,16-22 (Supplementary Fig. 4a–c). To probe the 
key interfaces (Fig. 3a–e) mutations were introduced into Ube2V2 and Ubc13 
and the modified proteins assayed. Ube2V2 F13 contacts Ubc13 (Fig. 3b) and 
Ube2V2 F13A, which was previously shown to perturb binding to Ubc13 in 
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yeast21, is almost completely inactive in ubiquitination (Fig. 3f). Ube2V2 S32 
forms a hydrogen bond with the backbone of the acceptor ubiquitin G47 (Fig. 
3a), and the importance of this residue in acceptor ubiquitin binding14 is 
consistent with the loss of activity of Ube2V2 S32A in ubiquitination (Fig. 3f) 
although there is almost no difference in the affinity for Ubc13 (Supplementary 
Fig. 5a, b). 
 
The C-terminus of the donor ubiquitin is locked down in the active site groove 
of Ubc13 (Fig. 3c) by RNF4. This appears to be a conserved arrangement for 
activation of the thioester between ubiquitin and ubiquitin-like proteins and 
their cognate E2s3-5,23,24 and was evident in the UbcH5A~Ub–RNF4 RING 
structure4. A hydrogen bond between the backbone of ubiquitin R74 and the 
side chain of D87 in UbcH5A was identified as critical as was D117 that was 
predicted to be involved in deprotonating and/or positioning the incoming 
lysine4,25. Equivalent mutations in Ubc13 (D89A, D119A) were also inactive 
(Fig. 3c, f), as were mutations disrupting interactions between the donor 
ubiquitin and Ubc13 (L106A) and between Ubc13 (R7A and M64A) and RNF4 
(Fig. 3 d–f). This suggests that RNF4 plays a similar role in Ubc13 catalysis 
by activating the thioester bond.  
 
Activation of Ubc13~Ub thioester by Ube2V2 and the RNF4 RING 
To establish the requirements for activation of the Ubc13~Ub thioester we 
carried out lysine discharge assays (the amino acid lysine acts as the 
substrate) on ubiquitin-loaded Ubc13 (Fig. 4a–c).  This eliminates any role of 
substrate in recognition and reports on the activation of the ubiquitin~E2 
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thioester bond. Unexpectedly, neither RNF4 nor a constitutively active RNF4 
fused to a second RNF4 RING domain (RNF4-RING, Fig. 4a) alone were able 
to substantially activate ubiquitin discharge from the Ubc13~ubiquitin 
conjugate. However, when both RNF4-RING and Ube2V2 were present the 
rate of ubiquitin discharge was dramatically increased. RNF4-RING was 
required as Ube2V2 alone had only a small effect on the rate of ubiquitin 
discharge. Binding of ubiquitin to Ube2V2 does not have a substantial impact 
on RNF4-mediated ubiquitin discharge from Ubc13 as Ube2V2 S32A that 
perturbs ubiquitin binding has almost wild-type activity (Fig 4b, c). 
 
We conclude that Ube2V2 and RNF4 together induce an active conformation 
of the Ubc13~Ub thioester. However, we do not identify any obvious structural 
changes at the E2 catalytic site that could explain the requirement for Ube2V2 
in RNF4 mediated Ubc13~Ub activation when comparing the Ubc13~Ub–
RNF4 RING complexes with and without Ube2V2 (Supplementary Fig. 2b). 
Moreover, the Ubc13~Ub–RNF4 RING structure is very similar to that of the 
catalytically active UbcH5A~Ub–RNF4 RING (Supplementary Fig. 2a). We 
note that our structures are isopeptide- rather than thioester-linked Ubc13~Ub 
conjugates and whilst simple modelling of the thioester does not reveal any 
change in the structure at the active site, the occurrence of subtle changes 
that could influence catalysis cannot be excluded.   
 
A key region in Ubc13 that is contacted by Ube2V2 is the D81 to R85 loop 
that is directly connected to the loop that includes the catalytic cysteine (K87 
in our structures) and to N79, a catalytically important residue that is thought 
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to stabilise the tetrahedral intermediate and support the active site loop26,27. 
The loop D81 to R85 of Ubc13 makes a number of contacts with Ube2V2, 
including a salt bridge between R85 of Ubc13 and E20 of Ube2V2 (Fig. 3c, 
Supplementary Fig. 6a, b). In testing the importance of this salt bridge, Ubc13 
R85S and R85E mutants were shown to have dramatically reduced catalytic 
activity but Ube2V2 E20A and E20R were fully active (Fig. 3f, Supplementary 
Fig. 6c). Moreover, a charge swap combination of Ubc13 R85E and Ube2V2 
E20R did not rescue activity (Supplementary Fig. 6c). This suggests that 
Ubc13 R85 has a critical role in maintaining the active site in an optimal 
conformation for catalysis, but this is not dependent on the salt bridge 
between Ubc13 R85 and Ube2V2 E20. The sequence of the D81 to R85 loop 
varies between different E2 enzymes (Supplementary Fig. 6d). Ubc13 D81 
can make several hydrogen bonds with the backbone of this loop and a salt 
bridge with R85 (Fig. 3c). In UbcH5A, N79 can make similar hydrogen bonds 
but as the equivalent residue of R85 in Ubc13 is S83 in UbcH5A there is no 
salt bridge (Supplementary 6a, b). Mutation D81A in yeast Ubc13 decreased 
the amount of di-ubiquitin formed compared to wild-type21. We could not 
express human Ubc13 D81A but Ubc13 D81N which preserves the hydrogen 
bonds with the loop backbone, had only modestly reduced activity 
(Supplementary Fig. 6c). Introduction of the R85S mutation into wild-type 
Ubc13 reduces activity dramatically (Fig. 3f). This mutation not only removes 
the electrostatic interactions with Ubc13 D81 and Ube2V2 E20, but is 
predicted to disrupt a number of hydrophobic interactions (Fig. 3b and 
Supplementary Fig. 6a). Ubc13 R85S increases the Kd for Ube2V2 by more 
than 30 times, while Ube2V2 E20A results in an increase of 4 times in the Kd 
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for WT Ubc13 (Supplementary Fig. 5a, b). However introduction of R85S in 
Ubc13 D81N is almost without consequence compared to Ubc13 D81N 
(Supplementary Fig. 6c). Thus it appears that R85 is essential only when the 
negatively charged D81 is present. We suggest that Ubc13 activation by 
Ube2V2 results from a change in the conformation or immobilisation of the 
R85–D81 interaction upon Ube2V2 binding which induces the catalytic 
configuration of the active site loop. 
 
DISCUSSION 
The structure we have determined is a model for the first step in the synthesis 
of polyubiquitin chains (Fig. 4d): that is the transfer of a donor ubiquitin from 
its E2 thioester conjugate to the K63 of the priming ubiquitin. To obtain this 
structure it was necessary to replace the reactive thioester between ubiquitin 
and Ubc13 by a stable isopeptide bond. Modelling the thioester in place of the 
isopeptide linkage and modifying the rotamer of the side chain of K63 of the 
acceptor ubiquitin (which is not well defined in the electron density maps, 
Supplementary Fig. 3b, c) brings K63 of the acceptor ubiquitin to within 9 Å of 
the carbonyl carbon of the thioester linkage. Crystal packing allowed us to 
capture the acceptor ubiquitin in the structure but the distortion from perfect 
nucleophilic attack geometry expected in solution may arise from both crystal 
packing and tethering of the ubiquitin to a Ubc13 molecule. In this situation 
the Ubc13–Ube2V2 interaction would dominate as this is a much higher 
affinity interaction (50 nM) than the Ub–Ube2V2 interaction (30 M)17. 
However a simple rigid body rotation of the ubiquitin by a few degrees or 
change in the precise position of a RING domain could reduce the distance to 
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within the range of nucleophilic attack. The value of the structure is that it has 
captured Ube2V2 bound to the acceptor ubiquitin with Lys63 in a position that 
could lead to attack on the linkage between the donor ubiquitin and Ubc13 
that is held in the active “folded back” conformation by the RING domain of 
RNF4. This allowed us to build a model for the RING mediated formation of 
K63 chains that was tested by mutagenesis and biochemical analysis. The 
arrangement in the active site is similar to that observed for the RBX1–
Ubc12~NEDD8–Cul1–DCN1 complex where the NEDD8 is “folded back” onto 
the E2, but where modeled lysine of the substrate, unaffected by crystal 
packing makes a much closer approach (2.6 Å) to the Ubc12~NEDD8 
linkage24. 
Synthesis of K63 linked ubiquitin chains onto a target protein is at the heart of 
many cellular processes. The structure reveals that Ube2V2 regulates this 
process by binding and presenting the priming ubiquitin such that its K63 
attacks the thioester linkage between the donor ubiquitin and Ubc13 (to which 
Ube2V2 also binds).  Our data show that in the presence of RNF4 Ube2V2 
has an additional role in increasing the reactivity of the Ubc13~Ub thioester 
linkage. Without Ube2V2, Ubc13 cannot efficiently transfer ubiquitin to any 
substrate. Thus only when Ube2V2 is bound and ubiquitin is presented in the 
correct spatial orientation is Ubc13 activated. Such exquisite and multi-
layered control is emerging as a common feature of ubiquitin28 and ubiquitin-
like23,24 modification systems.  
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Accession Codes: Coordinates and structure factors of the Ubc13~Ub–
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Figure Legends 
 
Figure 1: Biochemical analysis of RNF4 catalysed K63 linked 
polyubiquitination by Ube2V2–Ubc13 complex. 
 
(a) Cartoon representation of RNF4, 4xSUMO-2, and Ub~4xSUMO-2. RNF4 
contains four N-terminal SIMs (yellow) followed by a C-terminal RING domain 
(dark pink). 4xSUMO-2 contains four linearly fused SUMO-2 molecules (blue). 
Ub~4xSUMO-2 has a ubiquitin molecule (orange) linearly fused to the N-
terminus of 4xSUMO-2. 
 
(b) Coomassie-blue stained SDS-PAGE analysis of ubiquitination assays 
containing various combinations of Ube2V2, RNF4, Ub~4xSUMO-2, 
4xSUMO-2 and ATP. Time points are denoted above the gels. The red 
asterisk indicates formation of di-ubiquitin. 
 
Figure 2: Structure of ubiquitin loaded Ubc13 in complex with Ube2V2 
and the RING domain of RNF4 showing specificity for K63 linked 
polyubiquitination. 
 
(a) Ribbon (top) and cartoon (bottom) representation of Ube2V2 (dark and 
pale blue) and the linearly fused RING domain dimer of RNF4 (dark and pale 
pink) in complex with ubiquitin loaded Ubc13. Ubc13 is shown in dark and 
pale green while the donor ubiquitin is yellow and Ub* is coloured orange. 
Ubc13 K87 and donor ubiquitin G76 are highlighted in magenta with the 
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isopeptide linkage highlighted with a magenta sphere. Zn ions are shown as 
grey spheres.  
 
(b) Ribbon (top) and cartoon (bottom) representation of the ubiquitin-loaded 
Ubc13 in complex with the RING domain of RNF4. The colour scheme is the 
same as in a and the second donor ubiquitin is light orange. 
 
(c) Ribbon (left) and surface (right) representation of the same complex as in 
a where Ub* has been transformed in order to generate the canonical model. 
The colour scheme is the same as in a. Ub* K63 is coloured in yellow with th  
ε-amine highlighted with a yellow sphere. 
 
(d) Cartoon diagram of K63 linked chain formation based on the Ubc13~Ub– 
Ube2V2–RNF4 RING structure. 
 
Figure 3: Mutational analysis of the Ubc13~Ub–Ube2V2–RNF4 RING 
complex. 
 
(a) Detailed molecular interface between Ub* (orange) and Ube2V2 (blue) 
from the canonical model.  
 
(b) Detail of the hydrophobic pocket in Ubc13 (green) for Ube2V2 (blue). 
 
(c) Interaction between the C-terminal tail of the donor ubiquitin (yellow) and 
the active site groove of Ubc13 (green). K63 of Ub* (orange) is shown and the 
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distance between its amino group and the carbonyl carbon of the donor 
ubiquitin G76 is indicated. Interactions between the D81 to R85 loop of Ubc13 
and Ube2V2 (blue) are also shown. 
 
(d) The hydrophobic interface between Ubc13 (green) and ubiquitin (yellow) in 
the Ubc13~Ub conjugate bound to the RING domain of RNF4. 
 
(e) Molecular detail of the interaction surface between Ubc13 (green) and the 
RING domain of RNF4 (dark pink).  
 
(f) Coomassie-blue stained SDS-PAGE analysis of ubiquitination assays 
containing wild type (WT) or mutants of Ubc13 and Ube2V2. The red asterisk 
indicates formation of di-ubiquitin. 
 
Figure 4: Both Ube2V2 and dimeric RNF4 are required for activation of 
the Ubc13~Ub thioester conjugate. 
 
(a) Cartoon representation of RNF4 and RNF4-RING. RNF4-RING has a 
second RING domain of RNF4 (pale pink) linearly fused to RNF4. The RING 
domain dimer, which was used in crystallography, is highlighted with a black 
dotted line. 
 
(b) SYPRO orange stained SDS-PAGE analysis of lysine discharge assays in 
the presence of RNF4, RNF4-RING, WT Ube2V2 and Ube2V2 S32A. Time 
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points are denoted above each gel. Uncropped gels are available in 
Supplementary Data Set 1. 
 
(c) Reaction rates were obtained for lysine discharge assays shown in b. The 
reaction rates from two or three technical replicates are shown as black dots 
and the mean reaction rates are shown as black horizontal bars. Number of 
replicates (n) is denoted below the graph. Spreadsheet containing reaction 
rate calculations are available in Supplementary Data Set 2. 
 
(d) Schematic diagram of RNF4 catalysing the formation of K63 and K48 
linked polyubiquitin chains in complex with Ube2V2–Ubc13 and UbcH5A 
respectively. 
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Table 1  Data collection and refinement statistics (molecular replacement) 
 
 RING–Ubc13~Ub–
Ube2V2 
RING–
Ubc13~Ub 
Data collection   
Space group P3221 P21212 
Cell dimensions   
    a, b, c (Å) 77.5, 77.5, 328.4 69.2, 169.2, 52.6 
 ()  90.00, 90.00, 120.00 90.00, 90.00, 
90.00 
Resolution (Å) 67 - 3.4(3.49-3.40)a 32 – 2.21(2.26 – 
2.21) 
Rmerge   3.4(62.9) 6.2 (15.3) 
I / I 25.7(1.9) 20.9(7.8) 
Completeness (%) 88.9(98.3) 95.0(74.8) 
Redundancy 4.1(3.4) 5.7(3.7) 
   
Refinement   
Resolution (Å) 67 – 3.4 32 – 2.21 
No. reflections 14,864 30,359 
Rwork / Rfree 0.208 / 0.286 21.7 / 25.5 
No. atoms 6742 4591 
    Protein 6738 4524 
    Zn2+ 
    Ethylene glycol 
4 
0 
4 
24 (6 
molecules) 
    Water 0 33 
B factors   
    Protein 
    Zn2+ 
140 
117 
25 
17 
    Ethylene glycol - 19  
    Water - 18 
r.m.s. deviations   
    Bond lengths (Å) 0.014 0.014 
    Bond angles () 1.6 1.7 
One crystal per structure. aValues in parentheses are for highest-resolution shell. 
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Methods 
Cloning, expression and purification of recombinant proteins 
Rattus norvegicus RNF4 and linear fusions, RING-RING and RNF4-RING, 
were expressed and purified as described previously for WT RNF429. A linear 
fusion of four SUMO-2 molecules (4xSUMO-2) and ubiquitin and four SUMO-
2 molecules (Ub~4xSUMO-2) were expressed and purified as described 
previously15,29. Human Ube2V2 was subcloned into the pLou3 vector using 
NcoI & BamHI restriction sites. Human Ubc13 (also known as UBE2N) was 
subcloned into the pHISTEV30a vector using NcoI & HindIII restriction sites. 
C87K and K92A were introduced into Ubc13 by site-directed mutagenesis. 
His6-tagged Ubc13 and His6-MBP-tagged Ube2V2 were purified by Ni-NTA 
(Qiagen) affinity chromatography. To cleave off the His6-tag and His6-MBP-
tag, both proteins were incubated with TEV protease and dialyzed overnight 
into 50 mM Tris, 150 mM NaCl, 0.5 mM TCEP, pH 7.5. Any uncleaved protein, 
free His6-tag or His6-MBP-tag and TEV protease (also His6-tagged) were 
removed by Ni-NTA affinity chromatography. Untagged Ubc13 and Ube2V2 
were further purified by size exclusion chromatography using HiLoad 
Superdex 75 16/60 (GE Healthcare) and 20 mM Tris, 150 mM NaCl, 0.5 mM 
TCEP, pH 7.5 as running buffer. Cloning of Ubc13 and Ube2V2 yielded two 
extra residues (Gly-Ala) at the N-terminus of both proteins after cleavage with 
TEV protease. 
 
Preparation of isopeptide linked Ubc13~Ub conjugate 
Ubiquitin purified from bovine erythrocytes (U6253, Sigma-Aldrich) was used 
for conjugation to Ubc13 via an isopeptide linkage. A similar method was used 
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to load ubiquitin onto the active site of Ubc13 as used previously for a 
UbcH5A~Ub conjugate4. Ubc13 (100 μM) and ubiquitin (120 μM) and His6-
Ube1 (0.8 μM) were incubated together at 37 °C for 21 hours in 50 mM Tris 
pH 10.0, 150 mM NaCl, 3 mM ATP, 5 mM MgCl2 and 0.5 mM TCEP 
(Supplementary Fig. 1b). The isopeptide linked Ubc13~Ub conjugate was 
either purified directly or mixed in a 1:1 ratio with Ube2V2 and then purified by 
size exclusion chromatography on a HiLoad Superdex 75 16/60 (GE 
Healthcare) and 20 mM Tris, 150 mM NaCl, 0.5 mM TCEP, pH 7.5 as running 
buffer (Supplementary Fig. 1d). 
 
Crystallization of Ube2V2–Ubc13~Ub–RNF4 RING 
The Ube2V2–Ubc13~Ub complex was mixed in a 2:1 molar ratio with the 
RING-RING linear fusion in a buffer containing 20 mM Tris, 150 mM NaCl, 0.5 
mM TCEP, pH 7.0 and concentrated to 10 mg ml-1. Crystals of the complex 
were grown by sitting-drop vapour diffusion at 20 °C. 1.25 μl of protein was 
mixed with 1.25 μl of reservoir solution (16.7% (v/v) PEG MME 550, 0.1 M 
MES pH 7.0). Crystals appeared after a few hours and grew to their final size 
after 1 day. Crystals were cross-linked with glutaraldehyde for 30 minutes at 
20 °C by placing 2 μl of glutaraldehyde in the bottom of a PCR tube and 
inserting it into the reservoir well. Glutaraldehyde was removed and crystals 
were then immediately soaked in 15% (v/v) glycerol, 16.7% (v/v) PEG MME 
550, 0.1 M MES pH 7.0 and flash frozen in liquid N2.  
 
Crystallization of Ubc13~Ub–RNF4 RING 
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The Ubc13~Ub conjugate was mixed in a 2:1 molar ratio with the RING-RING 
linear fusion in a buffer containing 20 mM Tris, 150 mM NaCl, 0.5 mM TCEP, 
pH 7.0 and concentrated to 10 mg ml-1. Crystals of the complex were grown 
by sitting-drop vapour diffusion at 20 °C. 0.2 μl of protein was mixed with 0.2 
μl of reservoir solution (0.2 M MgCl2, 0.1 M Tris pH 8.5, 20% (w/v) PEG 
8000). Crystals appeared after 1 day and grew to their final size after 2 days. 
Crystals were soaked in a 2:1 ratio of reservoir solution and 100% ethylene 
glycol and flash frozen in liquid N2. 
 
Structure determination for Ube2V2–Ubc13~Ub–RNF4 RING and 
generation of the canonical model 
The long cell edge of the crystals required us to pre-orient the crystals for data 
collection to avoid overlaps. The crystals varied in quality and we screened 
multiple crystals. We collected the data on beamline IO4 at Diamond 
(wavelength 0.9795 Å) at 100 K using 0.2 oscillations for 400 images before 
the diffraction deteriorated.  The detector was positioned to ensure a clear 
separation of the spots rather than to maximize the resolution. Thus the 
highest resolution shell of data observed (3.49 to 3.4 Å) is incomplete, as it is 
located in the corners of the plate. The data in the next highest shell 3.58 to 
3.49 Å were 99% complete. Data were indexed, integrated and scaled using 
XIA2, XDS and CCP430-35. The structure was solved by molecular 
replacement using PHASER36. The model was refined using REFMAC537 and 
evaluated using MolProbity38. The final statistics are shown in Table 1. The 
coordinates and data are available at the RCSB with the accession code 5ait. 
The final model and electron density map for the donor and acceptor ubiquitin 
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at position K63 is shown (Supplementary Fig. 3 b–e). Looking at the crystal 
packing reveals the reason why one of the ubiquitin molecules is displaced; in 
the new position the ubiquitin makes extensive contacts with a symmetry 
related Ube2V2 molecule (Supplementary Fig. 3a). If one transforms this 
ubiquitin by the crystallographic operator -X+Y, -X, Z+1/3 then what we term 
the ‘canonical model’ can be generated (Fig. 2c). The canonical structure 
interfaces bury 750 Å2 more surface area than the original structure39. 
Although we discuss the canonical model, it is important to note that it is 
‘artificial’ and not found in solution. This is because the transformed ubiquitin 
is in reality covalently linked to Ubc13 (Chain E); the canonical model arises 
because of crystal packing. 
 
Data collection and structure determination for Ubc13~Ub–RNF4 RING 
Data were collected on a Rigaku Saturn 944+ CCD with a Rigaku MM007 
HFM generator (wavelength 1.54 Å) at 100 K using 0.25 oscillations for 720 
images. Data were indexed, integrated and scaled using XIA2, XDS and 
CCP430-35. The structure was solved by molecular replacement using 
PHASER36. Chains D and G are missing due to the absence of Ube2V2. The 
models were adjusted to fit electron density maps using COOT40. Residues 
H186 and K187 in the first RING domain and residues N185, H186, K187 and 
R188 from the second RING domain were not clearly visible in the electron 
density map and were therefore deleted from the model. Crystal packing with 
Ubc13 (Chain B) and ubiquitin (Chain C) from a symmetry related complex is 
the likely cause of disorder in these loops. The model was refined using 
REFMAC537 and evaluated using MolProbity38. The final statistics are shown 
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in Table 1 and the coordinates and data are available at the RCSB with the 
accession code 5aiu. 
 
Ubiquitination assay 
Ubiquitination assays were carried out as previously described12. The 
following components were mixed together and incubated at room 
temperature: 0.1 μM E1, 2.5 μM Ubc13, 2.5 μM Ube2V2, 0.55 μM RNF4, 5.5 
μM Ub~4xSUMO-2 or 4xSUMO-2, 20 μM Ub, 3 mM ATP, 5 mM MgCl2, 50 
mM Tris pH 7.5, 150 mM NaCl, 0.5 mM TCEP, 0.1 % NP40. The reaction was 
stopped with SDS-PAGE loading buffer and analyzed by SDS-PAGE. Gels 
were stained with Coomassie Blue. Time points were taken at 0, 2, 5, 10, 20, 
40, 60 and 100 min. The zero time point was taken before the addition of 
ATP. Reactions were also analyzed by western blotting with anti-ubiquitin 
antibody (Dako). 
 
Lysine discharge assay 
Ubc13~Ub thioester linked conjugate was prepared by mixing the following 
components for 15 min at 37 °C: 120 μM Ubc13, 100 μM Ub, 0.2 μM Ube1, 
50 mM Tris pH 7.5, 150 mM NaCl, 3 mM ATP, 5 mM MgCl2, 0.5 mM TCEP, 
0.1 % NP40. Apyrase (4.5 U ml−1, New England BioLabs) was then added to 
the reaction to deplete the ATP. The thioester was then mixed in a 1:1 ratio 
with different combinations of RNF4 constructs, Ube2V2 and L-lysine buffered 
with 50 mM Tris pH 7.5, 150 mM NaCl, 0.1 % NP40, 0.5 mM TCEP. The final 
concentration of each component is about 50 μM thioester, 150 mM L-lysine, 
100 μM Ube2V2 and 0.55 μM RNF4 or 0.275 μM RNF4-RING. The reaction 
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was incubated at room temperature and stopped with non-reducing SDS-
PAGE loading buffer and analyzed by SDS-PAGE. Gels were stained with 
SYPRO Orange (Life Technologies, S6650) and imaged using Bio-Rad gel 
doc with the SYPRO Ruby filter. The thioester was quantified using Image 
Lab. Reaction rates were derived from 4 – 6 time points in the linear range of 
the reaction. Individual reaction rates are shown for duplicate or triplicate 
reactions as well as the mean reaction rate. Zero time point was taken before 
the addition of RNF4, Ube2V2 and L-lysine. 
 
ITC experiment 
ITC experiments were performed on a MicroCal iTC 200 (GE Healthcare). All 
proteins were dialyzed overnight into degassed 50 mM Tris pH 7.5, 150 mM 
NaCl, 0.5 mM TCEP. Protein concentrations were determined by absorbance 
at 280 nm and extinction coefficients were predicted using ExPASy 
ProtParam tool. 250 – 370 μM WT Ube2V2 or Ube2V2 mutants were titrated 
into 25 – 37 μM WT Ubc13 or Ubc13 mutants. The experiment consisted of 
one injection of 0.5 μl followed by 1.8 μl injections. The injection speed was 
set to 1 μl s-1 with a 2-minute delay after each injection and the stirring speed 
was 750 RPM. A blank titration of WT Ube2V2 or Ube2V2 mutants was 
performed to account for the heat of dilution of Ube2V2 and subtracted from 
the experimental data. Raw data were analyzed using MicroCal Origin 
software. Data were fitted using a one-binding site model.  
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